Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

Table 2 Summary of patient characteristics at starting glatiramer acetate (N = 68)

Characteristics	Value
Age (years), mean ± SD	41.7 ± 9.5
Female, n (%)	48 (70.6)
Caucasian, n (%)	66 (97.1)
Multiple sclerosis duration (years), mean ± SD^a	7.6 ± 5.7
Previous interferon-β for multiple sclerosis, n (%):
IFN-β 1a sc	29 (42.6)
IFN-β 1a im	28 (41.2)
IFN-β 1b	22 (32.4)
Number of relapses from multiple sclerosis diagnosis, mean ± SD†	4.1 ± 3.4
EDSS score, mean ± SD	3.2 ± 4.1

^aMissing data, n = 5; †Missing data, n = 2
EDSS Expanded Disability Status Scale, im intramuscular, sc subcutaneous, SD standard deviation

ISSN: 2191-1991